Select Publications

1. Shaywitz AJ*, Courtney KD*, Patnaik A*, Cantley LC (*Equal contribution). PI3K Enters Beta Testing. Cell Metabolism. 2008; 8:179-81. PMCID: PMC3389549.

2. Patnaik A, Swanson KD, Csizmadia E, Solanki A, Landon-Brace N, Gehring M, Helenius K, Olson BM, Pyzer AR, Wang LC, Elemento O, Novak J, Thornley TB, Asara JM, Montaser L, Timmons JJ, Morgan TM, Wang Y, Levantini E, Clohessy JG, Kelly K, Pandolfi PP, Rosenblatt JM, Avigan DE, Ye H, Karp JM, Signoretti S, Balk SP and Cantley LC. Cabozantinib eradicates advanced murine prostate cancer by activating anti-tumor innate immunity. Cancer Discovery. 2017; 7(7):750-765. PMID: 28274958.

3. Sturey B, Patnaik A. Neutrophils and Anti-cancer Immunity: A Paradigm Shift in Cancer Immunotherapy. Oncoscience 2017; 4(11-12): 164-165. PMID: 29344550.

4. Olson B, Li Y, Lin Y, Liu E, Patnaik A. Co-clinical trials of Novel Immuno-Oncology combination therapies in mouse models of cancer. Cancer Discovery. 2018; 8(11):1358-65. PMID: 30309862.

5. Olson B, Patnaik A. Utilizing Precision Medicine to Modulate the Prostate Tumor Microenvironment and Enhance Immunotherapy. Urologic Oncology. 2018; S1078- 1439(18)30455-1. PMID: 30503851.

6. Carlo M, Giri V, Antonarakis E, Abida W, Alumkal J, Beer T, Beltran H, George D, Heath E, Higano C, McKay R, Morgans A, Patnaik A, Ryan C, Schaeffer E, Stadler W, Taplin M, Kauff N, Paller C, Vinson J, Cheng H. Evolving Intersection between Inherited Cancer Genetics and Therapeutic Clinical Trials in Prostate Cancer: A White Paper from the Germline Genetics Working Group of the Prostate Cancer Clinical Trials Consortium. JCO Precision Oncology. 2018; 1:1-14. PMID: 3076138.

7. Paller C, Antonarkis E, Beer T, Borno H, Carlo M, George D, Graff J, Gupta S, Health E, Higano C, McKay R, Morgans A, Patnaik A, Petrylak D, Rettig M, Ryan C, Taplin M, Whang Y, Vinson J, Cheng H, Giri V; PCCTC Germline Genetics Working Group. Germline Genetic Testing in Advanced Prostate Cancer; Practices and Barriers: Survey Results from the Germline Genetics Working Group of the Prostate Cancer Clinical Trials Consortium. Clinical Genitourinary Cancer. 2019; (4):275-282. PMID: 31171481. PMCID: PMC6662206.

8. Ascierto P, Campbell K, Daniele B, Dougan M, Emens L, Formenti S, Janku F, Khleif S, Kirchhoff T, Morabito A, Najjar Y, Odunsi K, Nathan P, Patnaik A, Paulos C, Reinfeld B, Skinner H, Timmerman J, Butterfield L, Puzanov I. Perspectives in immunotherapy: meeting report from the "Immunotherapy Bridge" (December 4th-5th, 2019, Naples, Italy). Journal of Translational Medicine. 2021; 19(1):13. PMID: 33407605. PMCID: PMC7789268.

9. Abida W, Campbell D, Patnaik A, Shapiro J, Sautois B, Vogelzang N, Voog E, Bryce A, McDermott R, Ricci F, Rowe J, Zhang J, Piulats J, Fizazi K, Merseberger A, Higano C, Krieger L, Ryan C, Feng F, Simmons A, Loehr A, Despain D, Dowson M, Green F, Watkins S, Golsorkhi T, Chowdhury S. Non-BRCA DNA damage repair gene alterations and response to the PARP inhibitor rucaparib in metastatic castration-resistant prostate cancer. Clinical Cancer Research. 2020; 26(11):2487-2496. PMID 32086346.

10. Abida W, Patnaik A, Campbell D, Shapiro J, Bryce A, McDermott R, Sautois B, Vogelzang N, Bambury R, Voog E, Zhang J, Piulats J, Ryan C, Merseburger A, Daugaard Heidenreich A, Fizazi K, Higano C, Krieger L, Sternberg C, Watkins S, Despain D, Simmons A, Loehr A, Dowson M, Golsorkhi T, Chowdhury, S. Rucaparib in men with metastatic castration-resistant prostate cancer harboring a BRCA1 or BRCA2 gene alteration. Journal of Clinical Oncology. 2020; 38(32):3763-3772. PMID: 32795228.

11. Sharma P, Pachynski R, Narayan V, Fléchon A, Gravis G, Galsky M, Mahammedi H, Patnaik A, Subudhi S, Ciprotti M, Simsek B, Saci A, Hu Y, Han G, Fizazi K. Nivolumab Plus Ipilimumab for Metastatic Castration-Resistant Prostate Cancer: Preliminary Analysis of Patients in the CheckMate 650 Trial. Cancer Cell. 2020; 38(4):489-499. PMID: 32916128.

12.  Kather J, Heij L, Grabsch H, Loeffler C, Echle A, Krause J, Muti H, Niehuis J, Sommer J, Bankhead P, Schulte J, Cipriani N, Ortiz-Brüchle N, Paner G, Patnaik A, Jäger D, Trautwein C, Van den Brandt P, Kooreman L, Pearson A, Luedde T. Pan-cancer image- based genetic testing. Nature Cancer. 2020; (1):789-799. PMID: 33763651. PMCID: PMC7610412.

13. Li Q, Liu K, Liu Q, Wang G, Jiang W, Meng Q, Yi Y, Yang Y, Wang R, Zhu S, Li C, Yan L, Zhang L, Zhao D, Kim J, Zu X, Kozielski A, Qian W, Chang J, Patnaik A, Chen K, Cao Q. Antihistamine Drug Ebastine Inhibits Cancer Growth by Targeting Polycomb Group Protein EZH2. Molecular Cancer Therapeutics. 2020; 19(10):2023-2033. PMID: 32855270.

14. McKay R, Morgans A, Paller C, Antonarkis E, Beer T, Borno H, Carlo M, George D, Graff J, Gupta S, Health E, Higano C, Patnaik A, Petrylak D, Rettig M, Ryan C, Taplin M, Whang Y, Vinson J, Giri V, Cheng H; PCCTC Germline Genetics Working Group. Current Guidelines, Practical Considerations and Challenges for Germline Genetic Testing in Prostate Cancer Patients. Journal of Oncology Practice. 2020; 17(4):275- 282. PMID: 32986533. PMCID: PMC6662206.

15. Chaudagar K*, Landon Brace N*, Solanki A*, Hieromnimon H, Hegerniller E, Li W, Shao Y, Joseph J, Wilkins D, Bynoe K, Li XL, Clohessy J, Ullas S, Karp J & Patnaik A. Cabozantinib unlocks efficient in vivo targeted delivery of neutrophil-loaded nanoparticles into murine prostate tumors. Molecular Cancer Therapeutics. 2021. 20(2):438-449. doi: 10.1158/1535-7163. MCT-20-0167. Epub 2020 Dec 4. PMID: 33277441.

16. Rameshbabu S*, Labadie B*, Argulian A, Patnaik A (Corresponding Author). Targeting Innate Immunity in Cancer Therapy. Vaccines 2021; 9(2):138. PMID: 33572196. PMCID: PMC7916062.

17. Ascierto P, Bifulco C, Ciardiello F, Demaria S, Emens L, Ferris R, Formenti S, Galon J, Khleif S, Kirchhoff T, McQuade J, Odunsi K, Patnaik A, Paulos C, Taube J, Timmerman J, Fox B, Hwu P, Puzanov I. Perspectives in immunotherapy: meeting report from the immunotherapy bridge (December 2nd-3rd, 2020, Italy). Journal of Translational Medicine. 2021; 19(1):238. PMID: 34078406.

18. Pienta K, Gorin M, Rowe S, Carroll P, Pouliot F, Probst S, Saperstein L, Preston M, Alva A, Patnaik A, Durack J, Stambler N, Lin T, Jensen J, Wong V, Siegel B, Morris M and OSPREY Study Group. A Phase 2/3 Prospective Multicentre Study of the Diagnostic Accuracy of Prostate-Specific Membrane Antigen (PSMA) PET/CT with 18 F-DCFPyL in Patients with Prostate Cancer (OSPREY). Journal of Urology. 2021; 206(1):52-61. PMID: 33634707.

19. Dutta Gupta P, Chaudagar K, Lin J-R, Sharma-Saha S, Bynoe K, Leung K, Shafran J, Helmi H, Maillat L, Heiss B, Paner G, Krishnan Y, Sorger P, Stadler W, & Patnaik A. PARP and PI3K inhibitor combination therapy eradicates c-MYC-driven murine prostate cancers via cGAS/STING pathway activation within tumor-associated macrophages. 2020; Pre-print: https://www.biorxiv.org/content/10.1101/2020.07.17.198598v1.